MIRA Pharmaceuticals, Inc. (MIRA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MIRA SEC filings page.
This page shows MIRA Pharmaceuticals, Inc. (MIRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MIRA remains pre-revenue, with operating losses funded mainly by external financing while FY2025 liquidity strengthened the balance sheet.
The key mismatch is between the net loss of$10.4M and operating cash flow of-$4.7M : accounting loss did not translate one-for-one into operating cash use. Financing supplied$8.2M in FY2025 as shares outstanding reached 42.0M, indicating that reported expansion depended on capital raised outside operations.
Total assets expanded from
With no revenue reported, the FY2025 expense base—SG&A of
Financial Health Signals
MIRA Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
MIRA Pharmaceuticals, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
MIRA Pharmaceuticals, Inc. reported a net loss of $10.4M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
MIRA Pharmaceuticals, Inc. reported -$1.2M in net income in Q2 2026. This represents an increase of 21.4% from the same quarter a year earlier. Against the prior quarter it is down 5.1%.
MIRA Pharmaceuticals, Inc. earned -$0.03 per diluted share (EPS) in Q2 2026. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
MIRA Pharmaceuticals, Inc. held $3.6M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
MIRA Pharmaceuticals, Inc.'s ROE was -14.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 255.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
MIRA Pharmaceuticals, Inc. invested $706K in research and development in Q2 2026. This represents an increase of 42.2% from the same quarter a year earlier. Against the prior quarter it is up 34.5%.
Not reported for Q2 2026.
Not reported for Q2 2026.
MIRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $706K+42.2% | $525K+66.9% | N/A | $413K-61.3% | $496K-19.2% | $314K-58.8% | N/A | $1.1M+5.1% |
| SG&A Expenses | $450K-57.1% | $579K-61.2% | N/A | $904K-10.8% | $1.0M-5.9% | $1.5M+48.2% | N/A | $1.0M-52.7% |
| Interest Expense | $35K+307.4% | $45K+309.6% | N/A | $16K+141.6% | $9K+121.9% | -$21K+57.5% | N/A | -$38K-108.8% |
| Net Income | -$1.2M+21.4% | -$1.2M+35.5% | N/A | -$1.1M+44.3% | -$1.5M+9.1% | -$1.8M-3.8% | N/A | -$2.0M+43.0% |
| EPS (Basic) | -$0.03+66.7% | -$0.03+72.7% | $0.10+166.7% | -$1.18-742.9% | -$0.09+18.2% | -$0.11+26.7% | -$0.15+62.5% | -$0.14+46.2% |
| EPS (Diluted) | -$0.03 | -$0.03 | $0.10 | -$1.18 | -$0.09+18.2% | -$0.11+26.7% | -$0.15+62.5% | -$0.14+46.2% |
| Diluted Shares (Avg) | N/A | N/A | N/A | 19M | 17M+14.9% | 17M+12.6% | N/A | 15M+10.5% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Operating Income, EBITDA, Income Tax.
MIRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.2M+844.7% | $9.5M+575.8% | $11.1M+279.5% | $7.6M+78.9% | $868K-71.2% | $1.4M-63.2% | $2.9M-40.7% | $4.3M-52.7% |
| Current Assets | $8.2M+880.7% | $9.4M+590.8% | $11.1M+282.9% | $7.6M+79.6% | $833K-71.6% | $1.4M-63.3% | $2.9M-40.6% | $4.2M-30.3% |
| Cash & Equivalents | $3.6M+394.1% | $4.8M+299.2% | $6.3M+124.0% | $2.6M-36.3% | $730K-74.1% | $1.2M-65.8% | $2.8M-38.4% | $4.1M-29.4% |
| Short-Term Investments | $4.5M | $4.6M | $4.7M | $4.9M | $0 | $0 | $0 | $0 |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $5K0.0% | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $41K-86.3% | $115K+8.1% | $702K-2.9% | $84K-87.9% | $298K-62.5% | $106K-83.7% | $723K+29.6% | $693K-23.3% |
| Current Liabilities | $41K-86.3% | $115K+8.1% | $702K-2.9% | $84K-87.9% | $298K-62.5% | $106K-83.7% | $723K+29.6% | $693K-20.2% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% |
| Total Equity | $8.2M+1332.3% | $9.3M+622.4% | $10.4M+372.4% | $7.5M+111.2% | $570K-74.3% | $1.3M-59.0% | $2.2M-49.7% | $3.6M-56.0% |
| Retained Earnings | -$41.9M-29.2% | -$40.7M-31.7% | -$39.6M-35.8% | -$33.6M-25.7% | -$32.5M-31.4% | -$30.9M-34.4% | -$29.1M-36.9% | -$26.7M-72.5% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
MIRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M-50.8% | -$1.2M+26.3% | -$1.1M+37.1% | -$1.1M+40.5% | -$800K+7.4% | -$1.6M-55.3% | -$1.8M-74.4% | -$1.8M-4.6% |
| Stock-Based Compensation | $22K-95.5% | $108K-87.7% | N/A | N/A | $490K | $875K+74.9% | N/A | N/A |
| Financing Cash Flow | $0-100.0% | -$331K-9878.4% | $4.8M+881.0% | $3.0M-4.9% | $324K+103.7% | $3K+113.9% | $493K+313.8% | $3.2M-58.4% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
MIRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -14.8%+255.0pp | -12.3%+125.5pp | N/A | -15.1%+42.1pp | -269.8%-193.6pp | -137.8%-83.4pp | N/A | -57.2%-13.0pp |
| Return on Assets | -14.7%+162.4pp | -12.2%+115.2pp | N/A | -14.9%+33.0pp | -177.1%-121.0pp | -127.4%-82.3pp | N/A | -47.9%-8.1pp |
| Current Ratio | 200.08+197.3x | 82.16+69.3x | 15.75+11.8x | 90.53+84.4x | 2.79-0.9x | 12.86+7.2x | 3.99-4.7x | 6.11-0.9x |
| Debt-to-Equity | 0.01-0.5x | 0.01-0.1x | 0.07-0.3x | 0.01-0.2x | 0.52+0.2x | 0.08-0.1x | 0.33+0.2x | 0.19+0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| MIRA Pharmaceuticals, Inc. MIRA | FY2025 | N/A | -$10.4M | N/A | $31.3M | — |
| Medicus Pharma Ltd. MDCX | FY2025 | N/A | -$47.3M | N/A | $138K | — |
| Scilex Holding Company SCLX | FY2025 | $30.3M | -$374.1M | N/A | $20.5M | 53/100 |
| SCYNEXIS, Inc. SCYX | FY2025 | $20.6M | -$8.6M | -41.8% | $40.6M | 50/100 |
| AYTU BioPharma, Inc. AYTU | FY2026 | $57.6M | -$14.3M | -24.8% | $22.0M | 47/100 |
| Talphera, Inc. TLPH | FY2025 | $28K | -$14.3M | N/A | $56.1M | — |
Where MIRA Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Is MIRA Pharmaceuticals, Inc. profitable?
No, MIRA Pharmaceuticals, Inc. (MIRA) reported a net income of -$10.4M in fiscal year 2025.
What is MIRA Pharmaceuticals, Inc.'s return on equity (ROE)?
MIRA Pharmaceuticals, Inc. (MIRA) has a return on equity of -100.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is MIRA Pharmaceuticals, Inc.'s operating cash flow?
MIRA Pharmaceuticals, Inc. (MIRA) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are MIRA Pharmaceuticals, Inc.'s total assets?
MIRA Pharmaceuticals, Inc. (MIRA) had $11.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does MIRA Pharmaceuticals, Inc. spend on research and development?
MIRA Pharmaceuticals, Inc. (MIRA) invested $1.7M in research and development during fiscal year 2025.
What is MIRA Pharmaceuticals, Inc.'s current ratio?
MIRA Pharmaceuticals, Inc. (MIRA) had a current ratio of 15.75 as of fiscal year 2025, which is generally considered healthy.
What is MIRA Pharmaceuticals, Inc.'s debt-to-equity ratio?
MIRA Pharmaceuticals, Inc. (MIRA) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is MIRA Pharmaceuticals, Inc.'s return on assets (ROA)?
MIRA Pharmaceuticals, Inc. (MIRA) had a return on assets of -94.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is MIRA Pharmaceuticals, Inc.'s P/E ratio?
MIRA Pharmaceuticals, Inc. (MIRA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $31.3M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MIRA Pharmaceuticals, Inc.'s price-to-sales ratio?
MIRA Pharmaceuticals, Inc. (MIRA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $31.3M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does MIRA Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, MIRA Pharmaceuticals, Inc. (MIRA) held $11.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.7M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is MIRA Pharmaceuticals, Inc.'s Piotroski F-Score?
MIRA Pharmaceuticals, Inc. (MIRA) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MIRA Pharmaceuticals, Inc.'s earnings high quality?
MIRA Pharmaceuticals, Inc. (MIRA) reported a net loss of $10.4M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.